ArticleNature communications2023
Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- pSIM: A next generationMolecular therapy. Advances · 2026Article
- Adapted Live SARS-CoV-2 Vaccine Elicits Rapid Mucosal Immunity, Protects From Disease, and Reduces Shedding of XBB.1.5.European journal of immunology · 2026Article
- Article
- Comparison of immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines against SARS-CoV-2.iScience · 2025Article
- An mRNA-based FimH nanoparticle vaccine against uropathogenicFrontiers in immunology · 2025Article
- mRNA vaccine-induced IgG mediates nasal SARS-CoV-2 clearance in mice.Molecular therapy. Nucleic acids · 2024Article
- Article
- Multivalent mRNA Vaccine Elicits Broad Protection against SARS-CoV-2 Variants of Concern.Vaccines · 2024Article
- Frameworks for transformational breakthroughs in RNA-based medicines.Nature reviews. Drug discovery · 2024Review
- Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection.Viruses · 2024Article
- Mucosal vaccine-induced cross-reactive CD8Nature immunology · 2024Article
- Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model.Scientific reports · 2024Article
- Article
- Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern.Journal of biomedical science · 2023Article
- Animal models for COVID-19 and tuberculosis.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combining optimized spike (S) protein-encoding mRNA vaccines to target multiple SARS-CoV-2 variants could improve control of the COVID-19 pandemic. We compare monovalent and bivalent mRNA vaccines encoding B.1.351 (Beta) and/or B.1.617.2 (Delta) SARS-CoV-2 S-protein in a transgenic mouse and a Wistar rat model. The blended low-dose bivalent mRNA vaccine contains half the mRNA of each respective monovalent vaccine, but induces comparable neutralizing antibody titres, enrichment of lung-resident memory CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.